clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder trea

Question

Travka [436]

11 months ago

15

clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder trea

ted with bcg immunotherapy

Computers and Technology

2 answers:

8_murik_8 [283] · Answer 1 · 2024-07-18T20:40:30+03:00

The summary of the research - clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG Immunotherapy is given below.

<h3>What is the summary of the above research?</h3>

Urinary bladder carcinoma in situ (CIS) is a flat, high-grade, and aggressive form of urothelial cancer with a high likelihood of development to muscle-invasive illness and metastatic dissemination.

The study's goal was to compare the clinical histories and survival rates of primary, secondary, and concurrent CIS of the bladder.

Learn more about Immunotherapy at brainly.com/question/14493516

#SPJ1

Juli2301 [7.4K] · Answer 2 · 2024-07-18T21:44:38+03:00

The summary of the research - clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG Immunotherapy is given below.

<h3>What is the summary of the above research?</h3>

Urinary bladder carcinoma in situ (CIS) is a flat, high-grade, and aggressive form of urothelial cancer with a high likelihood of development to muscle-invasive illness and metastatic dissemination.

The study's goal was to compare the clinical histories and survival rates of primary, secondary, and concurrent CIS of the bladder.

Learn more about Immunotherapy:

brainly.com/question/14493516?

#SPJ4